New drug combo tested for Tough-to-Treat leukemia
NCT ID NCT03118466
Summary
This study tested whether adding the drug lenalidomide to standard chemotherapy (MEC) works better for adults with acute myeloid leukemia (AML) that has returned or not responded to previous treatment. The goal was to see if this combination could help more patients achieve remission and stay in remission longer. The trial involved 41 participants and focused on measuring complete response rates and survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02062, United States
-
Massachusetts general Hospital
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.